{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia&page=95", "query": { "condition": "Leukemia", "page": 95 }, "page_size": 10 }, "pagination": { "page": 95, "page_size": 10, "total_count": 5292, "total_pages": 530, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia&page=96&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia&page=94&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T05:50:41.445Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03452774", "title": "SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer, Metastatic", "Cancer", "Cancer of Pancreas", "Cancer of Liver", "Cancer of Stomach", "Cancer Liver", "Cancer of Rectum", "Cancer of Kidney", "Cancer of Esophagus", "Cancer of Cervix", "Cancer of Colon", "Cancer of Larynx", "Cancer, Lung", "Cancer, Breast", "Cancer, Advanced", "Cancer Prostate", "Cancer of Neck", "Cancer of Skin", "Neuroendocrine Tumors", "Carcinoma", "Mismatch Repair Deficiency", "BRCA Gene Rearrangement", "Non Hodgkin Lymphoma", "Leukemia", "Non Small Cell Lung Cancer", "Cholangiocarcinoma", "Glioblastoma", "Central Nervous System Tumor", "Melanoma", "Urothelial Carcinoma", "Bladder Cancer", "Ovarian Cancer", "Endometrial Cancer", "Testicular Cancer", "Breast Cancer", "COVID", "Myelofibrosis", "Myeloproliferative Neoplasm", "Myeloproliferative Disorders", "Follicular Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Clinical Trial Matching", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Massive Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 50000, "start_date": "2018-01-01", "completion_date": "2040-06", "has_results": false, "last_update_posted_date": "2025-10-28", "last_synced_at": "2026-11-04T05:50:41.445Z", "location_count": 67, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 64 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03452774" }, { "nct_id": "NCT04849910", "title": "Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Acute", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "VOR33", "type": "BIOLOGICAL" }, { "name": "Mylotarg", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Vor Biopharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 67, "start_date": "2021-12-16", "completion_date": "2025-05-28", "has_results": false, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-11-04T05:50:41.445Z", "location_count": 14, "location_summary": "La Jolla, California • Stanford, California • Miami, Florida + 10 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04849910" }, { "nct_id": "NCT00002510", "title": "Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Temple University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "16 Years to 65 Years" }, "enrollment_count": null, "start_date": "1992-04", "completion_date": "2001-06", "has_results": false, "last_update_posted_date": "2010-10-01", "last_synced_at": "2026-11-04T05:50:41.445Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002510" }, { "nct_id": "NCT01831726", "title": "Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tumor Pathway Activations Inhibited by Dovitinib" ], "interventions": [ { "name": "Dovitinib (TKI258)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 80, "start_date": "2013-08", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-03-20", "last_synced_at": "2026-11-04T05:50:41.445Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Pismo Beach, California + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Pismo Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01831726" }, { "nct_id": "NCT00348985", "title": "PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Grade III Lymphomatoid Granulomatosis", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Primary Central Nervous System Hodgkin Lymphoma", "Primary Central Nervous System Non-Hodgkin Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Adult T-cell Leukemia/Lymphoma", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Small Lymphocytic Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "belinostat", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 55, "start_date": "2006-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-03", "last_synced_at": "2026-11-04T05:50:41.445Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00348985" }, { "nct_id": "NCT00004217", "title": "S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "valspodar", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "56 Years", "maximum_age": null, "sex": "ALL", "summary": "56 Years and older" }, "enrollment_count": 55, "start_date": "2000-02", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-11-04T05:50:41.445Z", "location_count": 89, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 57 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004217" }, { "nct_id": "NCT03484520", "title": "A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer - Acute Myeloid Leukemia" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Dinaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2018-07-23", "completion_date": "2022-12-01", "has_results": false, "last_update_posted_date": "2022-12-30", "last_synced_at": "2026-11-04T05:50:41.445Z", "location_count": 7, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 4 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03484520" }, { "nct_id": "NCT00003735", "title": "Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "topotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 11, "start_date": "1998-12", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2014-07-24", "last_synced_at": "2026-11-04T05:50:41.445Z", "location_count": 35, "location_summary": "Long Beach, California • Los Angeles, California • Orange, California + 27 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003735" }, { "nct_id": "NCT00004918", "title": "Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Myeloid Leukemia in Remission", "Chronic Phase Chronic Myelogenous Leukemia", "Previously Treated Myelodysplastic Syndromes", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Relapsing Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "PR1 leukemia peptide vaccine", "type": "BIOLOGICAL" }, { "name": "Montanide ISA 51 VG", "type": "DRUG" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 69, "start_date": "1999-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-07", "last_synced_at": "2026-11-04T05:50:41.445Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004918" }, { "nct_id": "NCT00186940", "title": "Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Leukemia", "Lymphoma", "Tumor Lysis Syndrome", "Hyperuricemia" ], "interventions": [ { "name": "Rasburicase", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 16, "start_date": "2005-03", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2017-04-25", "last_synced_at": "2026-11-04T05:50:41.445Z", "location_count": 11, "location_summary": "Palo Alto, California • San Diego, California • Indianapolis, Indiana + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00186940" } ] }